Editas Medicine, Inc. Overview
Pro stress-test →Editas Medicine is a genome-editing company developing transformative genomic medicines using a proprietary CRISPR technology platform including CRISPR/Cas9, CRISPR/Cas12a, and foundational intellectual property for both systems. The company is a clinical-stage gene editing company focused on in vivo CRISPR-based medicines, positioning itself at the forefront of precision genetic medicine.
Strategic Profile
Pro stress-test →Editas's lead in vivo development candidate, EDIT-401, is designed as a one-time treatment for hyperlipidemia through LDLR gene editing and has shown substantial LDL-C reductions in preclinical models. The company engages in collaborations, including with Bristol Myers Squibb and Vertex Pharmaceuticals, while advancing its pipeline. Its differentiation lies in proprietary lipid nanoparticle delivery and gene upregulation strategies targeting liver and blood cell therapies.
Competitive Landscape
Pro stress-test →Editas competes within the gene editing space against Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, Prime Medicine, Fate Therapeutics, Sangamo Therapeutics, Precision BioSciences, and others. The competitive advantage hinges on proprietary CRISPR platform efficiency, delivery mechanisms, and clinical trial success timelines in the nascent field.
Industry Context
Editas Medicine, Inc. operates in Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector.
Key facts
Founded: 2013 · Headquarters: Cambridge, US · Employees: 246 · Revenue: $0.03B · Market cap: $0.21B